Cerebrolysin (brain peptides)

packaging available:
2ml x 10pcs
5ml x 5pcs
10ml x 5pcs
20ml x 5pcs

Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate the blood-brain barrier and directly enter nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.
a) metabolic regulation: Cerebrolysin increases the efficiency of aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.
b) neuroprotection: Cerebrolysin protects neurons from the damaging effects of lactic acidosis, prevents the formation of free radicals, increases survival and prevents the death of neurons under conditions of hypoxia and ischemia, reduces the damaging neurotoxic effect of excitatory amino acids (glutamate).
c) neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity, similar to the action of natural neuronal growth factors (NGF), but manifested under conditions of peripheral administration.
d) functional neuromodulation: Cerebrolysin has a positive effect in cases of cognitive impairment and on memory processes

1 ml of solution contains:
active ingredient: Cerebrolysin® concentrate (complex of peptides obtained from pig brain) 215.2 mg;
excipients: sodium hydroxide, water for injection.

Contraindications
- individual intolerance to the drug
-severe renal failure
-status epilepticus
With caution: the drug is used for allergic diathesis, diseases of an epileptic nature, including generalized epilepsy, due to a possible increase in the frequency of attacks.
USE IN PREGNANCY AND BREASTFEEDING
During pregnancy and breastfeeding, Cerebrolysin should be used only after a thorough analysis of the relationship between the positive effect of treatment and the risk associated with it. The results of experimental studies do not give reason to believe that Cerebrolysin has any teratogenic effect or has a toxic effect on the fetus. However, similar clinical studies have not been conducted.

It is used parenterally. Doses and duration of treatment depend on the nature and severity of the disease, as well as the age of the patient. It is possible to prescribe single doses, the value of which can reach 50 ml, but it is more preferable to carry out a course of treatment.
The recommended optimal course of treatment is daily injections for 10-20 days.
• Acute conditions (ischemic stroke, traumatic brain injury, complications of neurosurgical operations): from 10 ml to 50 ml
• In the residual period of cerebral stroke and traumatic injury to the brain and spinal cord: from 5 ml to 50 ml
• For psychoorganic syndrome and depression: from 5 ml to 30 ml
• For Alzheimer's disease, vascular dementia and combined Alzheimer's-vascular origin: from 5 ml to 30 ml
• In neuropediatric practice: 0.1-0.2 ml/kg body weight
To increase the effectiveness of treatment, repeated courses can be carried out as long as the patient's condition improves as a result of treatment.
After the first course, the frequency of dosing can be reduced to 2 or 3 times a week.
Cerebrolysin is used by injection: intramuscularly (up to 5 ml) and intravenously (up to 10 ml).
Doses from 10 ml to 50 ml are recommended to be administered only by slow intravenous infusion after dilution with the suggested standard solutions for infusion.
The duration of the infusion ranges from 15 to 60 minutes.